Paper

Cost-effectiveness of BRCA1/BRCA2 variant reclassification and recontact for hereditary breast and ovarian cancer in the United States

Genetics in Medicine · 2026 · Gregory F Guzauskas, Sara M Berger, Robert O'Connor et al.